Mercury Biopharmaceutical Corporation (TPEX:6932)
Taiwan
· Delayed Price · Currency is TWD 12.90
+0.30 (2.38%)
Apr 24, 2025, 1:28 PM CST
Mercury Biopharmaceutical Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 68.01 | 44.29 | 31.94 | 2.56 | 0.09 | Upgrade
|
| Short-Term Investments | 162.8 | 284.78 | 108.7 | - | - | Upgrade
|
| Cash & Short-Term Investments | 230.81 | 329.07 | 140.64 | 2.56 | 0.09 | Upgrade
|
| Cash Growth | -29.86% | 133.99% | 5391.45% | 2877.91% | -43.79% | Upgrade
|
| Other Receivables | 0.53 | 0.23 | 2.46 | - | - | Upgrade
|
| Receivables | 0.53 | 0.23 | 2.46 | - | - | Upgrade
|
| Prepaid Expenses | 11.38 | 10.07 | 2.64 | - | 0.01 | Upgrade
|
| Other Current Assets | 0.18 | 0.55 | - | 1.37 | - | Upgrade
|
| Total Current Assets | 242.9 | 339.93 | 145.73 | 3.93 | 0.1 | Upgrade
|
| Property, Plant & Equipment | 94.41 | 79.94 | 75.15 | 8.46 | - | Upgrade
|
| Other Intangible Assets | 4.53 | 2.71 | 0.5 | 0.49 | - | Upgrade
|
| Other Long-Term Assets | 11.37 | 15.5 | 8.55 | 0.51 | - | Upgrade
|
| Total Assets | 353.2 | 438.08 | 229.93 | 13.38 | 0.1 | Upgrade
|
| Accrued Expenses | - | - | 4.61 | 0.66 | 0.01 | Upgrade
|
| Short-Term Debt | - | - | - | - | 0.3 | Upgrade
|
| Current Portion of Long-Term Debt | 1.21 | - | - | - | - | Upgrade
|
| Current Portion of Leases | 2.6 | 0.68 | 1.05 | 0.79 | - | Upgrade
|
| Current Unearned Revenue | 5.48 | 0.44 | - | - | - | Upgrade
|
| Other Current Liabilities | 9.94 | 6.93 | 1.57 | 0.26 | - | Upgrade
|
| Total Current Liabilities | 19.24 | 8.05 | 7.23 | 1.7 | 0.31 | Upgrade
|
| Long-Term Debt | 40.39 | 41.6 | 41.6 | - | - | Upgrade
|
| Long-Term Leases | 3.31 | 0.07 | 0.77 | 1.22 | - | Upgrade
|
| Total Liabilities | 62.93 | 49.72 | 49.6 | 2.93 | 0.31 | Upgrade
|
| Common Stock | 105.46 | 103.99 | 100.87 | 15.4 | 0.2 | Upgrade
|
| Additional Paid-In Capital | 291.29 | 328.17 | 110.72 | 0.37 | - | Upgrade
|
| Retained Earnings | -50.57 | -43.82 | -31.25 | -5.31 | -0.41 | Upgrade
|
| Treasury Stock | -56.24 | - | - | - | - | Upgrade
|
| Comprehensive Income & Other | 0.33 | 0.01 | - | - | - | Upgrade
|
| Shareholders' Equity | 290.27 | 388.35 | 180.33 | 10.46 | -0.21 | Upgrade
|
| Total Liabilities & Equity | 353.2 | 438.08 | 229.93 | 13.38 | 0.1 | Upgrade
|
| Total Debt | 47.51 | 42.35 | 43.42 | 2.01 | 0.3 | Upgrade
|
| Net Cash (Debt) | 183.3 | 286.73 | 97.21 | 0.55 | -0.21 | Upgrade
|
| Net Cash Growth | -36.07% | 194.94% | 17575.09% | - | - | Upgrade
|
| Net Cash Per Share | 0.43 | 0.72 | 0.26 | 0.00 | -0.00 | Upgrade
|
| Filing Date Shares Outstanding | 421.85 | 415.96 | 403.46 | 403.46 | 104 | Upgrade
|
| Total Common Shares Outstanding | 421.85 | 415.96 | 403.46 | 307.94 | 104 | Upgrade
|
| Working Capital | 223.66 | 331.88 | 138.5 | 2.22 | -0.21 | Upgrade
|
| Book Value Per Share | 0.69 | 0.93 | 0.45 | 0.03 | -0.00 | Upgrade
|
| Tangible Book Value | 285.75 | 385.65 | 179.83 | 9.97 | -0.21 | Upgrade
|
| Tangible Book Value Per Share | 0.68 | 0.93 | 0.45 | 0.03 | -0.00 | Upgrade
|
| Land | - | - | 41.9 | - | - | Upgrade
|
| Buildings | - | - | 18.12 | - | - | Upgrade
|
| Machinery | - | - | 6.42 | 5.88 | - | Upgrade
|
| Construction In Progress | - | - | 7.5 | - | - | Upgrade
|
| Leasehold Improvements | - | - | 0.91 | 0.91 | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.